Compare Global X Lithium & Battery Tech ETF (LIT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Organon & Co. Common Stock — how do they compare? Global X Lithium & Battery Tech ETF trades at $65 (market cap $1.45B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 2.5× Global X Lithium & Battery Tech ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 57 Days and Organon & Co. Common Stock for 0 Days on average.
| LIT | OGN | |
|---|---|---|
Market Cap | $1.45B | $3.62B |
Volume | 191,139 | 2,892,999 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $13.81 |
52-Week Low | $56.39 | $5.70 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $67.65, down 1.05% with bearish technical signals from moving averages and oscillators. The ETF faces headwinds from volatile lithium prices and oversupply concerns, though long-term prospects remain supported by EV adoption trends. Recent news highlights significant short interest reduction and China's ambitious 30% EV fleet target by 2030.
Outlook is cautious near-term due to technical weakness and commodity volatility, but structural EV growth offers recovery potential. Risks include lithium price swings and geopolitical trade tensions, while institutional sentiment shows mixed signals with recent short covering.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
